Detalhe da pesquisa
1.
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Br J Haematol
; 185(3): 450-467, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30729512
2.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
3.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
4.
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 15(8): 874-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24948586
5.
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study.
Bone Marrow Transplant
; 57(10): 1507-1513, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35768571
6.
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma.
Oncogene
; 39(27): 5001-5014, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32523091
7.
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
Bone Marrow Transplant
; 59(3): 431-434, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195983
8.
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
J Clin Oncol
; 37(19): 1617-1628, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30969846
9.
Patient perceptions of second transplants in myeloma: impact on recruitment in the British Society of Blood and Marrow Transplantation/UK Myeloma Forum Myeloma X Relapse (Intensive) Trial.
Br J Haematol
; 163(4): 541-3, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24033132
10.
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
Cancer Res
; 66(12): 6379-86, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16778216
11.
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Lancet Haematol
; 3(7): e340-51, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27374467
12.
Novel uses for recombinant erythropoietin therapy in unlicensed indications.
Hematol J
; 5(2): 181-5, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15048070
13.
Adiponectin is produced by lymphocytes and is a negative regulator of granulopoiesis.
J Leukoc Biol
; 88(4): 807-11, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20643815
14.
Thalidomide-induced phrenic nerve paralysis.
Leuk Lymphoma
; 51(2): 342-4, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20038224
15.
The endogenous granulocyte colony-stimulating factor response following autologous peripheral blood stem cell transplantation is impaired in patients with myeloma.
Br J Haematol
; 117(3): 646-9, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12028037
16.
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Lancet Oncol
; 7(11): 958-9, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17081923
17.
Bone marrow architecture in acute myeloid/erythroid leukaemia.
Br J Haematol
; 126(1): 1, 2004 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15198725